jan 31, 2025 volume 34

EuroDURG BULLETIN

NEWSLETTER of the EUROPEAN CHAPTER of the SPECIAL INTEREST GROUP of
DRUG UTILISATION RESEARCH (SIG-DUR) of
the INTERNATIONAL SOCIETY OF PHARMACOEPIDEMIOLOGY (ISPE)



Welcome message from the chair

by Elisabetta Poluzzi

2024 has been really intensive for the EuroDURG community. We gave a strong contribution to ISPE conference held in Berlin in August 2024, in close collaboration with ISPE SIG DUR, by organising seminars and presenting results of drug utilization (DU) ongoing studies: methods in DU, network initiatives of data collection on emerging regulatory and clinical issues, interactions with other areas of pharmacoepidemiology (e.g., drug safety, planetary health).

EuroDURG European Drug Utilization Research Group

ispe International Society for Pharmacoepidemiology

Content

We also launched and presented the second edition of the book “Drug Utilisation Research - Methods and Applications” now available on the market. This book was edited and authored by many EuroDURGers, under the main coordination of Monique Elseviers.

We initiated a series of webinars and many DURGers attended (March and December 2024). They were focused on “Biologics’ drug utilisation mapping” and on “Healthcare data networks”, respectively; future webinars are under planning, and we invite EuroDURGers to propose their topic of interest. We also provided a periodically updated list of possible research grants for either consolidated research groups or promising young researchers: it may support future research network applications involving DUR topics.

Last June, EuroDURG summer School in Villnius pooled young DURGers in a



Elisabetta Poluzzi
Department of Medical and Surgical Sciences, pharmacology, University of Bologna, Italy

stimulating and vibrant week of work.

EuroDURG is currently busy organising the next conference, which will take place in Uppsala (Sweden) on July 1-4, 2025. EuroDURG conferences give our community the opportunity to share ongoing projects, as well as future perspectives of our growing research area.

All activities are reported on the LinkedIn and X (former Twitter) EuroDURG accounts.

Past events

In June 2024 Drug Utilization Research Summer School was held in Vilnius. PhD students, researchers and civil servants/public health officials from 9 countries had joined the intensive 5 days course. Various interactive sessions were organized from methods to specific therapeutic areas. In the small group seminars, participants developed their projects.

DURGers





Overall, participants were satisfied with comprehensive course, practical sessions and networking opportunities. The participants had the opportunity to work on the project following the lectures and go back home with a practical achievement.

by Indrė Trečiokienė





Project examples developed by the participants:

"Medication adherence"

"Opioid prescribing"

"Migraine treatment needs biological prophylaxis"

"Risk minimisation measures on valproate use"

"Harnessing data power"

"Pharmacovigilance concerns"

"Utilisation of electronic drug interaction system"

Report on European Projects

DURDAM - Drug Utilisation Research Databases Appraisal of Maturity

The DURDAM project seeks consensus on dimensions of drug utilization dataset maturity, laying the groundwork for a Drug Utilization (DU) database maturity appraisal tool. The aim of this study is twofold: determine whether the maturity of drug utilization (DU) databases used in DUR could be appraised and, if so, to build a maturity appraisal tool. First part of the project was finalised in June 2024. In three eDelphi rounds consensus on key attributes that can be used to assess maturity drug utilization datasets was reached with input from 22 international experts in various relevant fields, leading to the development of a framework for the DUR maturity appraisal tool. In this framework statements relating to DU database maturity addressing comprehensiveness, completeness, and accessibility achieved consensus with over 75% agreement. Following steps include development, accessibility testing and validation of the DU Databases Appraisal Tool.

by Indrė Trečiokienė and Sean MacBride-Stewart

The EMMA project (Exposure to Medications Measured using the ATC/DDD classification system)

The project was launched on December 2023 with the aim of fostering reproducibility and comparability of studies using the ATC/DDD standard through three distinct initiatives: the global EMMA survey, which aims to collect nation-level information on the implementation and maintenance of the ATC/DDD index, is now being distributed to over 50 different countries internationally; within the EMMA scoping review, that has the objective of documenting how pharmacoepidemiologists have recently reported on the use ATC/DDD methodology in the literature published since 2023, almost 20,000 abstracts were screened and data extraction from approximately 130 papers meeting inclusion is ongoing; Third, the EMMA DPP calculator task force, that aims to develop recommendations for the design and creation of a prototype online application for the easy-to-use certified calculation of number of DDD per medicinal product package (DPP) is going to be kicked-off in February 2025. Lastly, we are delighted to report that the manuscript proposal “Use of the ATC/DDD methodology in drug utilization and pharmacoepidemiological research: recommendations on best reporting practice” was awarded funding through the ISPE-funded manuscript initiative.

by Giuseppe Roberto, Rosa Gini and Mina Tadrus

COST ENABLE Action finalized

The EU-funded European Network to Advance Best practices & technoLogy on medication adherencE (ENABLE) project reached its goal in 2024. During four years, the project managed to create a multidisciplinary network of 200 researchers from 40 European countries, focusing on the promotion and adoption of Medication Adherence Technologies (MATech) across Europe. Since Medication Adherence is a key component of drug utilization, many researchers from EuroDURG were active in the ENABLE project all along the four years.
Information on the ENABLE achievement can be found in the final report. A number of publications assessed the current barriers and facilitators for using MATech, an open access repository of available technologies has been launched and potential implementation pathways have been identified in all European countries. Overall, the ENABLE network published 20 scientific papers during the course of the Action, but findings have also been disseminated via video animations, blogs, social media and a comic. All key results were disseminated during the World Adherence Forum, a 1-day stakeholder event organized in Brussels in end of August with participation from around 70 representatives from healthcare professional organizations, MAtech and pharmaceutical companies, patient organizations and the World Health Organisation (WHO).

During the meeting, key recommendations from the ENABLE project were formulated.

Reference:Van Boven JFM, Dima AL, Wettermark B, Potočnjak I, Ágh T; ENABLE collaborators. Leveraging digital medication adherence technologies to enhance sustainability of European health systems: ENABLE's key recommendations. Lancet Reg Health Eur. 2024 Dec 3;48:101164. doi: 10.1016/j.lanepe.2024.101164. More information is also still found on the project website https://enableadherence.eu/

by Bjorn Wettermark.

MEDSHARE-Rx Study: Exploring Nonrecreational Prescription Medicine Sharing Across Countries

The MEDSHARE-Rx Study aims to investigate the practices and reasons behind nonrecreational prescription medicine sharing across different countries. This cross-sectional study will address key questions, including the frequency of medicine sharing, the types of drugs most often shared, and how socio-demographic factors such as age, gender, and education influence these behaviors.
The study will utilize both pharmacy-based and mail survey data collection methods. By comparing practices across countries, the project seeks to uncover cultural, economic, and healthcare system-related differences influencing medication-sharing behaviors.

by Nataliia Khanyk

Cross-national study of biologicals

Biopharmaceuticals account for an increasing proportion of all new pharmaceuticals being introduced on the European market. They have the opportunity to improve quality of life and reduce mortality in treatment of many diseases, but there are challenges related to their comparatively high price and need for additional healthcare resources. Prior studies have shown that the adoption of new medicines varies widely between different countries, but few studies have focused on biopharmaceuticals. During 2023-2024, Ivar Veszelei, a master student in Uppsala university conducted a study to assess the availability of health authority data and variation in the early diffusion of biopharmaceuticals across Europe. With the help of EuroDURG, data were collected for 17 biopharmaceuticals, approved between 2015 and 2019. The study assessed data availability, diffusion rates, measured as Defined Daily Doses per 1,000 inhabitants, as well as relative rankings between countries during the first four years following market authorization.
By the end of 2024, twenty countries and two regions out of 31 European countries had provided data on biopharmaceutical utilization for out-of-hospital care, 15 provided wholesaler data, and 14 provided hospital data. A scientific paper has been submitted, and the study findings will be presented at the EuroDURG conference in Uppsala. For more information – welcome to contact Ivar Veszelei - iveszelei@gmail.com

The prevalence of polypharmacy in Europe – collaboration of EuroDURG and IQVIA

Our study on the prevalence of polypharmacy in Europe was published in the British Journal of Clinical Pharmacology! This was the result of the fruitful collaboration of EuroDURG with IQVIA. Marion Bennie, the first author, was invited by the journal to give a presentation about our study in September, because it was among the most frequently downloaded articles after it became available online. A sign of the big interest of the community in this topic. A big thank you to all collaborators on this project.
The article is published with open access and can be found here: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.16113
Full reference: Bennie M, Santa-Ana-Tellez Y, Galistiani GF, Trehony J, Despres J, Jouaville LS, Poluzzi E, Morin L, Schubert I, MacBride-Stewart S, Elseviers M, Nasuti P, Taxis K. The prevalence of polypharmacy in older Europeans: A multi-national database study of general practitioner prescribing. Br J Clin Pharmacol. 2024 Sep;90(9):2124-2136.

by Katja Taxis

What is already known about this subject

- In an ageing European population, multimorbidity and associated polypharmacy, including potentially inappropriate medication (PIM), are an increasing challenge for health systems.
- There is a lack of crossnational studies, using standardized methodology and comparable study populations, to determine the prevalence of polypharmacy and PIM use in primary care across Europe.

What this study adds

- More than half of older people were prescribied ≥5 drugs in four of the six countries.
- High usage of PPIs and benzodiazepines is concerning given the known adverse effects and should be a focus for polypharmacy management.
- Crossnational studies using routine data is an efficient tool for surveillance and evaluation.

Executive committee meetings






European Medicines Agency (EMA) activities

The integration of big data and advanced analytics is increasingly pivotal in enhancing drug regulatory decisions, with the European Medicines Agency (EMA) leading these efforts within the EU. In 2024, the EMA and the Heads of Medicines Agencies (HMA) have made significant progress through their Big Data Steering Group (BDSG) initiatives to advance data-driven regulation. The Data Analysis and Real World Interrogation Network (DARWIN EU) has grown to include 20 data partners, granting access to data from approximately 130 million patients across 15 European countries. Additionally, the EMA-HMA catalogues of real-world data sources and non-interventional studies were launched to improve data discoverability. In November 2024, a Real-World Data (RWD) quality framework was released for public consultation to elevate data quality standards.

To strengthen the EU network's analytical capacity, the EMA introduced five modules of the Data Science curriculum in September 2024, covering topics such as Big Data essentials, Artificial Intelligence (AI), Data Management, Data Visualization, and an Introduction to Data Science. Further, the Modules 'Study Protocol' and 'Statistical methods applied to RWE' were released in December, as part of the Pharmacoepidemiology and RWE curriculum. The BDSG also published its second report on real-world data studies, documenting 41 studies conducted from February 2023 to February 2024, to support the integration of real-world evidence into research and regulatory processes.

International collaboration continues to be a cornerstone of EMA's strategy. In 2024, key achievements include the establishment of the Real-World Evidence (RWE) group for public health emergencies by the International Coalition of Medicines Regulatory Authorities (ICMRA) in July 2024 and the adoption of a reflection paper on harmonisation of RWE terminology by the International Council for Harmonisation (ICH) in June 2024.

The year also saw advancements in technological infrastructure, with a review of the European Medicines Regulatory Network's computing capabilities completed in May 2024. Additionally, the first AI-enabled Scientific Explorer knowledge mining tool for EU regulators was launched in March 2024.
Progress has also been made in veterinary medicine. The fourth Veterinary Big Data Stakeholder Forum, held in October 2024, highlighted transformational opportunities for the regulation of veterinary medicinal products, as outlined in the European Veterinary Big Data Strategy 2022-2027. EMA initiatives continue to empower researchers and clinicians with cutting-edge tools, methodologies, and data to drive impactful drug utilization studies, ultimately improving patient care and public health outcomes.

by Katarina Gvozdanović and Carla Torre

ENCePP activities

The 2024 ENCePP plenary, organized on 22th of November, reflected the work conducted during the last year and informed the community on recent progress. The ENCePP workplan for 2024-2026 was published on the website in June 2024 and presented the milestones and deliverables (https://encepp.europa.eu/document/download/ec2097da-a30b-4155-84b7-38dac1f50592_en?filename=ENCePP%20Workplan_June%202024.pdf), which were updated during the plenary.
One of the main achievements reported for the ENCePP community was in February 2024, when the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have launched the electronic Catalogues of RWD sources and studies, replacing the former ENCePP Resource Database and EU PAS Register. EMA's goal is to make these Catalogues a central, comprehensive repository containing metadata information from as many data sources as possible across Europe and beyond. The HMA-EMA Catalogues of real-world data studies can now be accessed via the EMA website (https://catalogues.ema.europa.eu/). A refreshed ENCePP website has also been launched with a new design and new ENCePP logo (https://encepp.europa.eu/).

Data holders are invited to add information about their data source directly in the Catalogues following this link: https://catalogues.ema.europa.eu/catalogue-rwd-sources or by sending an email to RWDcatalogues@ema.europa.eu. Also, EMA is interested in hearing about the experience of the users. Feedback can be provided on the usability, functionalities, and more, by completing the short survey by 17 January 2025 (https://ec.europa.eu/eusurvey/runner/HMA_EMA_RWD_Catalogues).
The joint HMA-EMA Big Data Steering Group (BDSG) has launched a public consultation on the draft real-world data (RWD) chapter of the Data quality framework for EU medicines regulation, and the input can be sent by 31 January 2025.

(https://encepp.europa.eu/newsroom/news/public-consultation-rwd-chapter-data-quality-framework-2024-12-05_en).

The ENCePP Working Group on independence and transparency (WG2) initiated a podcast series 'Conduct your study', with various topics to be addressed. In the first episode (November 2024), Rosa Gini, chair of WG2, talks with Barbara Mintzes, Professor of evidence-based pharmaceutical policy at University of Sydney, about the ENCePP Code of Conduct. In the second episode (January 2025), Shirley Wang, Associate Professor of Medicine at Harvard Medical School, and Anton Pottegård, Professor of pharmacoepidemiology and clinical pharmacy at University of Southern Denmark, discuss about scientific independence, transparency, and the role of the ENCePP Code of Conduct to support investigators (https://encepp.europa.eu/newsroom/news/second-episode-conduct-your-study-podcast-series-online-2025-01-10_en).
Another deliverable on the ENCePP workplan is to update ENCePP governance and the way of working, with regards to Working Groups (WGs) and Special Interest Groups (SIGs), better aligned with EMA strategy and activities. There is an open call for ENCePP members to propose new WGs/SIGs.

Katarina Gvozdanović and Irina Iaru

NuPHac activities

NuPhaC (Nurse and Pharmaceutical Care) is an international expert consortium focused on the role of nurses in interprofessional pharmaceutical care. Last year, Switzerland, represented by Jenny Gentizon, and Ireland, represented by Jill Murphy, joined the network. It is wonderful to collaborate with so many experts who are truly dedicated to making a difference. Several new projects were initiated, interventions tested, articles published, and results presented at conferences and symposia. Here are some highlights:

Normally, we focus solely on pharmaceutical care-related research. However, since COVID-19, we have observed that every research project is significantly impacted by staff shortages. Healthcare systems are under pressure, and staff shortages pose a severe threat to care quality. When it is no longer possible to provide the basic care needed for patients, there is limited time for healthcare providers to participate in research and innovate. In every pharmaceutical care project, the impact of staff shortages must be considered. Response rates have declined, and only interventions that save time and increase efficiency attract organizational participation. Differences between countries affect the valorization potential of research results. Nevertheless, innovation and valorization can be part of the solution in these challenging circumstances.

In the Equanu project, we collected data for the third year in several European countries on the societal and professional recognition of nurses and their autonomy in advanced roles, for example in pharmaceutical care. This data collection is part of a 9-year cohort study comparing societal and professional recognition across European countries and tracking its evolution over the decade.

We held our NuPhaC Winter conference on December 13th and 14th in Antwerp. It was a perfect opportunity for collaboration and discussion. We are planning the next conference in Coimbra, Portugal.

Nurse prescribing is already permitted in many European countries. In some countries, new legislation has been published, and nurse prescribing will be implemented. Currently, we are creating a dedicated network on nurse prescribing in Europe within NuPhaC. The goal is to strengthen evidence, increase efficiency, quality, and effectiveness, and support policymaking at the European level. If you are interested in joining, please contact us at nuphac@uantwerpen.be.

NuPhaC
Nurse and Pharmaceutical Care

In the DepEnd project, we are investigating the impact of deprescribing medicines on the quality of life, mortality, hospitalizations, and other factors using health claims data and BelRAI data of deceased nursing home residents. While using population data can be very useful, it also presents challenges related to GDPR regulations, linking procedures, data errors, high costs, general data quality, and availability. As we analyze the data and prepare to publish the results in the upcoming year, we would like to discuss and publish about the challenges of using population data/healthcare claims data for research on medicine use. If you have experience with using population data/healthcare claims data on medicine use and are interested in publishing together about the challenges, please contact Degefaye.Anlay@uantwerpen.be.

And a NuPhaC-book is coming. We are still in conception status. The outline has been defined. The allocation of authors to chapters is nearly finished. The publisher is waiting for our final outline. The book will address nurses' roles, evidence-based practices and innovations in pharmaceutical care. The aim is to translate research into a book that can be used by nurses and nurse students that are expected to take up advanced roles. Are you now feeling some frustration because you did not have the opportunity to contribute to the book, you can still contact Manuel Lillo Crespo (University of Alicante) Manuellillocrespo@gmail.com .

by Tinne Dilles

EACPT activities

The European Association for Clinical Pharmacology and Therapeutics (EACPT) has just announced the program for its highly anticipated 2025 Congress in Helsinki, Finland, which will take place from 28 June to 1 July 2025. Held at the prestigious main building of the University of Helsinki, this event promises to be a remarkable gathering of experts in clinical pharmacology, therapeutics, and related fields.

A LOOK BACK: EACPT 2024 IN ROTTERDAM

Before we dive into the excitement of EACPT 2025, let's take a quick look at the successful 2024 congress held in Rotterdam. The scientific program of EACPT2024 was a fantastic success, and now the highlights are available in pictures and the final abstract book. The abstract book is an excellent resource for those unable to attend or who wish to revisit the cutting-edge presentations, providing a comprehensive overview of the discussions and findings shared at the event.

What's Coming at EACPT 2025 in Helsinki?

EACPT 2025 is shaping up to be a pivotal event in the field. Expect a robust scientific program filled with thought-provoking sessions, expert speakers, and opportunities to network with fellow professionals. The focus will continue to be on advancing the science of clinical pharmacology and improving patient care through evidence-based therapeutic practices.

Whether you're a researcher, clinician, or pharmacologist, EACPT 2025 in Helsinki will provide you with the tools, knowledge, and connections to drive innovation in your work. Stay tuned for further updates as we get closer to the congress!

by Gaye Hafez

ESCP activities

The next ESCP Workshop takes place in Egmond aan Zee, Netherlands on 7-8 April 2025, on the theme "The prescribing pharmacist: a prescription for better patient care". The deadline for abstract submission is 23-1-2025.

The Autumn Symposium will be held in the WTC in Grenoble, France, on 26-27-28 November 2025. The theme will be "From interprofessional education to interprofessional practice".
Interesting: Each year, ESCP awards financial support to attend the symposium. ESCP actively promotes the education of clinical pharmacists from developing countries. One way of doing this is to make the ESCP Symposium more accessible to pharmacists from these countries by offering financial support.

For more information see: https://escpweb.org/workshops-and-symposia/upcoming-events/
We plan to sign a memorandum of understanding to more closely collaborate with ESCP in the future. We keep you updated on the developments.

by Katja Taxis

Subgroups in EuroDURG



Research funding initiative

The subgroup "research funding initiative" was established at the beginning of 2024. Laura Sahm, Gaye Hafez, Ramune Jacobsen and Tinne Dilles took on the responsibility for this project. During various WG meetings, they explored and discussed funding opportunities. The findings were compiled into a comprehensive overview for the executive board members and the entire EuroDURG community through social media, aimed at supporting research collaboration and facilitating international student and staff exchanges.



Webinar series

A new series of EuroDURG webinars has started in 2024. At the first event in June 2024, Ivar Veszelei analysed the early diffusion of biopharmaceuticals in several European countries. The second webinar in December focussed on the European Health Data Space and data protection issues. Speakers were Carla Torre, Diogo Almeida and Ylenia Ingrasciotta. Also during 2025, EuroDURG plans to host several webinars, and topics from the whole range of drug utilisation research are being invited.
If you would like to suggest a topic or present your own research in this format, please contact Carlotta Lunghi carlotta.lunghi@unibo.it and Irene Langner Irene.Langner@wido.bv.aok.de.

We'd love to hear from you!

Got a topic or speaker in mind for a webinar on drug utilization research? We'd love to hear your suggestions! Feel free to reach out to us via email or through our social media channels. All contact details can be found at the end of this bulletin.
We look forward to your input!

www.pharmacoepi.org/eurodurg/

DURbook: Drug Utilization Research: Methods and Applications, second edition

The 27th of August 2024, during the ISPE meeting in Berlin, we officially launched the second edition of our DURbook. Thanks to the sustained efforts of 19 editorial EuroDURG board members and with the participation of 97 authors, and 67 external reviewers, we reached this result after five years of intense collaboration.

The book of 588 pages consists of four overarching sections: introduction, methods, applications and a new fourth section on the globalization of DUR. New chapters were added covering topics such as aggregate level analyses of DU data, artificial intelligence/machine learning, ethical aspects in DUR, and environmental pharmacoepidemiology. More than in the previous edition, the application section focuses on specific challenges, and expands on how to deal with these, keeping in mind the educational purpose of the book. We hope that this second edition of the DURbook will become a helpful tool and a source of inspiration for all teachers and researchers working with DU data.

by Monique Elsevier

You can order the DURbook in printed or electronic format via the Wiley Online Library bookstore using the following references:
Drug Utilization Research - Methods and Applications, 2nd Edition
Online ISBN/Product ID: 9781119911685
Print ISBN: 9781119911654 Copyright: 2024

Book launch Berlin: all book authors at the ISPE conference assembled for this historical picture

Glasgow Declaration: Increasing Access to Drug Utilization Data

The EuroDURG community initiated an action to increase access to drug utilization (DU) data during the EuroDURG Conference in Glasgow in November 2017. A definitive version of the Declaration was presented at the EuroDURG conference in Szeged, Hungary in 2020. This was followed by an engagement of ISPE with their endorsement of the Declaration secured in February 2022. In 2024, the Declaration was made available on the ISPE website and distributed to international and national organizations involved in the health care of patients at the global or national level. Additionally, the declaration has been disseminated using social media with a call for endorsement. All these forms of support will be assembled and brought to the attention of health policymakers, calling for improved DU data availability and accessibility with the ultimate goal of improving health care for all, at the national and global level.

If you haven't joined us in this call yet, please use the following link to endorse the Glasgow Declaration as an individual subscriber and/or in the name of your organization.

Glasgow Declaration - International Society for Pharmacoepidemiology

ISPE SIG DUR UPDATE 2024-2025



It's been another busy year for ISPE DUR SIG, with several activities, and oral and poster presentations at the 2024 ISPE Annual Meeting in Berlin. Highlights include:

- Pre-conference courses Introduction to Drug Utilisation and Advanced Drug Utilisation, were very well attended with very positive feedback from participants.
- DUR SIG Spotlight Poster Walk, with Shaleesa Ledlie from The University of Toronto being the prize winner presenting her work "Population-level utilization of direct-acting antiviral agents and trends in hepatitis C related hospitalizations".
- Two DUR Symposia "From a Pill to the Planet: Addressing Healthcare Sustainability through Pharmaco-epidemiologic Research" led by Bjorn Wettermark and Johanna Villen and "The Growing Global Problem of Drug Shortages: Understanding Their Impact on Research, Patients and Healthcare Systems" led by Mina Tadrous.
- Launch of the 2nd Edition of the "Drug Utilization Research Methods and Applications Textbook".

We are also planning an online DUR symposium in the first half of the year, which will be a great opportunity for students and early career researchers to present study findings or protocols. Stay tuned to the ISPE Exchange site.

Thanks! Gillian Caughey

European Drug Utilization Conference 2025

Bridging Data, Policy & Patients in Drug Utilization Research

July 01-04, 2025

Uppsala, Sweden

EuroDURG ispe

Abstract submission deadline 14.02.2025

The most awaited event by the EuroDurg community – EuroDurg Conference 2025 – will be held at Uppsala University, the oldest university in the north this July. As the healthcare landscape increasingly relies on data-driven approaches to inform policy and improve patient outcomes and drug utilisation research plays a critical role in optimising medication use, reducing waste, and addressing disparities in access and adherence, the theme of the conference is "Bridging Data, Policy & Patients in Drug Utilization Research". The integration of these domains is essential in responding to evolving challenges and can foster actionable insights that align healthcare systems with real-world needs, ensuring safer, more effective therapies for all.

The conference will start with MORE Europa project-supported satellite sessions and educational sessions. The plenary and keynote sessions this year will focus on:

- Informing drug policy decisions on access to medicines
- AI as aid and challenge
- One Health and Drug Utilization
- Evidence generation for the introduction of new drugs using RWD
- Health literacy and patient engagement

EuroDURG
European Drug Utilization Research Group

ispe
International Society for Pharmacoepidemiology

UPPSALA UNIVERSITET







There will also be dedicated workshops/symposiums on cross-national comparisons, the use of the DUR book as research and educational assistant, challenges and progress in research in different regions and communication between professionals and the public. The programme, registration and travel information is available at the conference website.

Delegates from a wide background of experience and disciplines including academia, healthcare organizations and health authorities are welcome to participate.

Program AT A GLANCE

	TUESDAY 1 JULY			WEDNESDAY 2 JULY			THURSDAY 3 JULY			FRIDAY 4 JULY		
				SCIENTIFIC PROGRAM PART I			SCIENTIFIC PROGRAM PART III			SCIENTIFIC PROGRAM PART V		
09.00 - 10.30	**SATELLITE PROGRAM** Real-world data to support regulatory decision-making with methodological examples from the More-EUROPA project *(separate registration is required)*			**WELCOME** **PLENARY 1:** Informing drug policy decisions in accessibility and equity in medicine use			**T-KL5/OC3** Accessibility of medicines	**T- KL6/OC4** Drugs & Environment	**T-KL7/OC5** Methods in DUR	**F-KL10/OC8** DUR in specific therapeutic areas	**F-KL11/OC9** Digitalization, Big Data and AI in DUR	**F-KL12/OC10** DUR in vulnerable populations
10.30-11.00				*Coffee break*			*Coffee break*			*Coffee break*		
11.00-12.30				**W-KL1/OC1** Adherence	**W-KL2/OC2** Crisis preparedness		**T- KL8/OC6** Polypharmacy	**T-KL9/OC7** DUR and safety		**PLENARY 3:** One Health and DUR **12:30** **Closing session**		
12.30-13.30				*Lunch* *("Newcomer" session)*			*Lunch*					
	EDUCATIONAL SESSIONS			SCIENTIFIC PROGRAM PART II			SCIENTIFIC PROGRAM PART IV					
13.30-14.15	**14:00** Welcome to the educational sessions			**W-KL3** EG for the introduction of new drugs using RWD	**W-KL4** Health literacy and patient engagement		**PLENARY 2:** AI as aid and challenge					
14.15-15.45	**T-ES1** Introduction to DUR	**T-ES2** Qualitative/ quantitative mixed methods	**T-ES3** Measuring medication adherence	**W-PSOC1** Posters and short oral communications all Conference DUR topics			**T-PSOC2** Posters and short oral communications all Conference DUR topics					
15.45-16.15	*Coffee break*			*Coffee break*			*Coffee break*					
16.15-17.45	**T-ES4** Critical appraisal of statistics in DUR	**T-ES5** Longitudinal DU studies	**T-ES6** Environmental DUR	**W-WS1** Cross-national comparisons	**W-WS2** DUR book: use as research and educational assistant	**W-WS3** *(Hospital pharmacy)*	**T-WS3** Global environment in DUR: challenges and progress in research in different regions	**T-WS4** Communication between professionals and the public				
19:00	***Welcome reception***			*EuroDURG general assembly*			***EuroDURG party with dinner***					

Legend

ES	*educational session*
KL	*key lecture*
OC	*oral communication*
PSOC	*poster and short oral communications*
WS	*workshop*

EG *evidence generation*
DU(R) *drug utilization (research)*
AI *artificial intelligence*
RWD *real-world data*

Discover the conferences this year

Spring Workshop of the European Society of Clinical Pharmacy (ESCP)
· Theme: The Prescribing Pharmacist: a Prescription for better patient care
· Egmond aan Zee, the Netherlands
· 7 – 8 April 2025

ISPOR 2025
· Montreal, Canada
· 13 – 16 May 2025

Nordic Social Pharmacy Conference
· Theme: Vulnerable Patient Populations and Health Inequalities
· Glasgow, UK
· 4 – 6 June 2025

Hungarian Society of Experimental and Clinical Pharmacology (HUPHAR) International Pharmacology Conference
· Theme: Focus on drug discovery and innovation
· Mátraháza, Hungary
· 4 – 6 June 2025

European Drug Utilization Conference 2025
· Theme: Bridging Data, Policy & Patients in Drug Utilization Research
· Uppsala, Sweden
· 1 – 4 July, 2025

41st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)
· Washington DC, USA
· 22 – 26 August 2025

83rd International Federation of Pharmacists (FIP) World Congress of Pharmacy and Pharmaceutical Sciences
· Theme: Pharmacy forward: Performance, Collaboration, and Health Transformation
· Copenhagen, Denmark
· 31 August – 3 September 2025



ISPOR Europe 2025
· Glasgow, UK
· 9 – 12 November 2025

18th European Public Health Conference 2025
· Theme: Investing for sustainable health and well-being
· Helsinki, Finland
· 11 – 14 November 2025

Executive committee 2023–25

Elisabetta Poluzzi (Chair)
Bologna, Italy
E-mail: elisabetta.poluzzi@unibo.it

Katja Taxis (Past Chair)
Groningen, The Netherlands
E-mail: k.taxis@rug.nl

Björn Wettermark
Uppsala, Sweden
e-mail: bjorn.wettermark@farmaci.uu.se

Ria Benko (Secretary)
Szeged, Hungary
E-mail: benkoria@gmail.com

Irina Iaru (Co-secretary)
Cluj-Napoca, Romania
E-mail: Cazacu.Irina@umfcluj.ro

Tinne Dilles
Antwerp, Belgium
E-mail: tinne.dilles@uantwerpen.be

Irene Langner
Berlin, Germany
E-mail: irene.langner@wido.bv.aok.de

Carlotta Lunghi
Bologna, Italy
E-mail: carlotta.lunghi@unibo.it

Verica Ivanovska
Stip, Fyr Macedonia
E-mail: vericaivanovska@hotmail.com

Katarina Gvozdanovic
Zagreb, Croatia
E-mail: katarina.gvozdanovic@gmail.com

Gaye Hafez
Istanbul, Turkey
E-mail: gaye.hafez@altinbas.edu.tr
gayehfz@gmail.com

Ramune Jacobsen
Copenhagen, Denmark
E-mail: ramune.jacobsen@sund.ku.dk

Sean MacBride Stewart
Glasgow, Scotland
E-mail: sean.macbride-stewart@ggc.scot.nhs.uk

Tanja Mueller
Glasgow, Scotland
E-mail: tanja.muller@strath.ac.uk

Lotte Rasmussen
Odense C, Denmark
E-mail: lorasmussen@health.sdu.dk

Laura J Sahm
Cork, Ireland
E-mail: L.Sahm@ucc.ie

Gabriel Sanfelix-Gimeno
Valencia, Spain
E-mail: sanfelix_gab@gva.es

Live Storehagen Dansie
Oslo, Norway
E-mail: livestorehagen.dansie@fhi.no

Ana Tomas Petrovic
Novi Sad, Serbia
E-mail: ana.tomas@mf.uns.ac.rs

Nataliia Khanyk
Ukraine
Uppsala University, Sweden
E-mail: nataliia.khanyk@farmaci.uu.se

Carla Torre
Lisboa, Portugal
E-mail: carla.torre@ff.ulisboa.pt

Indre Treciokiene
Vilnius, Lithuania
E-mail: indre.treciokiene@mf.vu.lt

Sabine Vogler
Vienna, Austria
Email: sabine.vogler@goeg.at

Martin Wawruch
Bratislava, Slovakia
Email martin.wawruch@gmail.com

EuroDURG on SOCIAL MEDIA



You can find us on LinkedIn and Twitter (now X) to stay up to date with all the activities we have planned for 2025. It has now been four years since we have launched our social media pages to easily disseminate EuroDURG activities. In the past year, we have provided updates on projects, publications, but the main focus was put on the EuroDURG 2024 summer school in Vilnius and EuroDURG members presentations and DUR book launch event during the ISPE conference in Berlin. Thanks for everyone who tagged the pages in many posts this year, which we were happy to repost and help increase visibility. We ended the year focusing on promoting the European Drug Utilization Conference 2025 to be held in Uppsala in July 2025.

Our social media community is growing in numbers, and we would like to thank everyone who is following us and interacting with our updates. Our Twitter (now X) page has been launched in June 2021 and has now reached a total of 240 followers. Just during the past year, our LinkedIn page follower number has almost doubled, reaching more than 700 followers.
We look forward to growing our network further, and we count on you, like-minded DUR enthusiasts, to make that happen. Follow us!

editors

The Bulletin was prepared by the EuroDURG ExCo members.
See contributors below each part. The photos are made public with permission or from personal collections.
Edited by Gaye Hafez, Irina Iaru and Ria Benko. Send reactions to benkoria@gmail.com

contact

For social media updates contact
Ana Tomas Petrović
Irina Iaru
https://www.pharmacoepi.org/eurodurg/